152 related articles for article (PubMed ID: 19740389)
21. Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?
Assi T; Cesne AL
Future Oncol; 2023 Sep; 19(28):1893-1896. PubMed ID: 37781755
[No Abstract] [Full Text] [Related]
22. Trabectedin: novel insights in the treatment of advanced sarcoma.
Lopez JP; Gajdos C; Elias A
Curr Oncol Rep; 2014 Jun; 16(6):387. PubMed ID: 24756367
[TBL] [Abstract][Full Text] [Related]
23. Trabectedin tactics: from sea squirts to sarcomas.
Randall RL; Cable MG
Lancet Oncol; 2015 Mar; 16(3):243-4. PubMed ID: 25752546
[No Abstract] [Full Text] [Related]
24. Trabectedin in soft tissue sarcomas.
Petek BJ; Loggers ET; Pollack SM; Jones RL
Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
[TBL] [Abstract][Full Text] [Related]
25. Trabectedin for the treatment of soft tissue sarcomas.
De Sanctis R; Marrari A; Santoro A
Expert Opin Pharmacother; 2016 Aug; 17(11):1569-77. PubMed ID: 27328277
[TBL] [Abstract][Full Text] [Related]
26. Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma.
Pick AM; Nystrom KK
J Oncol Pharm Pract; 2010 Dec; 16(4):269-72. PubMed ID: 20015930
[TBL] [Abstract][Full Text] [Related]
27. Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.
Ueda T; Kakunaga S; Ando M; Yonemori K; Sugiura H; Yamada K; Kawai A
Invest New Drugs; 2014 Aug; 32(4):691-9. PubMed ID: 24696229
[TBL] [Abstract][Full Text] [Related]
28. A review of the efficacy of trabectedin as second-line treatment of advanced soft tissue sarcoma.
Le Cesne A; Martín-Broto J; Grignani G
Future Oncol; 2022 Sep; 18(30s):5-11. PubMed ID: 36200935
[TBL] [Abstract][Full Text] [Related]
29. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Martin-Liberal J; Judson I
Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
[TBL] [Abstract][Full Text] [Related]
30. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
[TBL] [Abstract][Full Text] [Related]
31. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Gordon EM; Sankhala KK; Chawla N; Chawla SP
Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
[TBL] [Abstract][Full Text] [Related]
32. Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.
Vincenzi B; Badalamenti G; Armento G; Silletta M; Spalato Ceruso M; Catania G; Napolitano A; Maltese G; Valeri S; Incorvaia L; Santini D; Tonini G
Oncology; 2018; 95(1):1-7. PubMed ID: 29510410
[TBL] [Abstract][Full Text] [Related]
33. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
34. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Le Cesne A
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
[TBL] [Abstract][Full Text] [Related]
35. Acute myeloid leukemia unlikely related to trabectedin treatment.
Cartoafa M; Kahatt C; Soto-Matos A; Roy E; Lardelli P
Acta Haematol; 2011; 126(4):238-9; author reply 240. PubMed ID: 21952689
[No Abstract] [Full Text] [Related]
36. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
38. Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
Chaigneau L; Jary M; Nerich V; Hervieu A; Aubry S; Charon Barra C; Meynard G; Neumann F; Kalbacher E; Isambert N
Oncology; 2022; 100(12):633-644. PubMed ID: 36283345
[TBL] [Abstract][Full Text] [Related]
39. Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Digklia A; Coukos G; Homicsko K
Clin Cancer Res; 2022 May; 28(9):1745-1747. PubMed ID: 35176150
[TBL] [Abstract][Full Text] [Related]
40. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
